

## **Biologics Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)**

Market Report | 2026-05-20 | 350 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$4949.00
- Five User License \$5949.00
- Corporate License \$6969.00

### **Report description:**

The biologics market was valued at USD 409.40 Billion in 2025 . It is poised to grow at a CAGR of 7.20% during the forecast period of 2026-2035, and reach USD 820.53 Billion by 2035 . Rising prevalence of chronic diseases, increasing demand for targeted therapies, and advancements in biotechnology are driving market growth, supported by strong pipelines, regulatory approvals, and expanding healthcare infrastructure globally.

### Key Market Trends and Insights

- Based on region, North America held the largest revenue share of nearly 44% during the historical period.
- Based on the indication segment, oncology dominated the market with a share of more than 28% during the historical period.
- Based on product, the monoclonal antibodies segment accounted for a share of above 66% during the historical period.

### Market Size and Forecast

- Market Size (2025): USD 409.40 Billion
- Projected Market Size (2035): USD 820.53 Billion
- CAGR (2026-2035): 7.20%

### Biologics Market Overview

The biologics market is witnessing strong growth driven by rising demand for targeted therapies, increasing chronic disease prevalence, and continuous innovation in advanced therapeutics. Expanding applications in oncology and immunology are accelerating adoption globally, particularly with the growing use of monoclonal antibody treatments. Supportive regulatory frameworks and growing investment in research and development are further strengthening market expansion, while

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

advancements in manufacturing technologies continue to enhance production efficiency and accessibility of biologic treatments. The market reached a value of approximately USD 409.40 Billion in 2025 .

## Biologics Market Growth Drivers

### Rising FDA Support for Biosimilar Approvals Driving the Market Value

Regulatory reforms and biologics approvals are catalyzing industry growth. For instance, in March 2026, the U.S. FDA issued new draft guidance aimed at simplifying biosimilar development by easing testing requirements and reducing costs up to 50%, potentially enabling broader market access and increased competition among high-cost biologic therapies. This initiative is expected to accelerate development timelines and expand treatment choices for patients globally.

## Biologics Market Trends

Key trends shaping the biologics market include rising adoption of monoclonal antibody therapies, expanding biomanufacturing capabilities, increasing biologic approvals, and growing investment in antibody-drug conjugates globally.

### Rising Strategic Partnerships Boosting the Market Expansion

Strategic collaborations are strengthening biologics pipelines worldwide and strengthening the market. For instance, in February 2026, Eli Lilly and Innovent Biologics entered a USD 8.8 billion agreement to co-develop multiple monoclonal antibody therapies across oncology and immunology. The partnership extends beyond traditional licensing, focusing on early-stage research, clinical development, and commercialization of antibody-based biologics. This move is expected to strengthen Lilly's global biologics pipeline, enhance cross-border R&D capabilities, and drive next-generation therapeutic advancements.

## Biologics Market Segmentation

### Market Breakup by Source

- Microbial
- Mammalian

### Market Breakup by Product

- Monoclonal Antibodies
  - ??- Human mABs
  - ??- Humanized mABs
  - ??- Chimeric mABs
  - ??- Murine mABs
- Vaccines
- Recombinant Proteins
- Antisense, RNAi & molecular therapy
- Cell Based Therapies
  - ??- Stem Cell Therapy
  - ??- CAR-T Cell Therapy

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Tissue Engineering
- Others

#### Market Breakup by Indication

- Oncology
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others

#### Market Breakup by Distribution Channel

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

#### Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

#### Biologics Market Share

##### Oncology Expected to Dominate the Market Segment by Indication

Based on the indication segment, oncology dominated the market with a share of more than 28% during the historical period. This leadership is driven by increasing adoption of targeted therapies, particularly monoclonal antibody treatments, across various cancer types. Rising cancer prevalence, strong clinical efficacy, and continuous innovation in biologic therapies have further strengthened demand, supporting sustained growth of the oncology segment within the global biologics market.

##### Biologics Market Analysis by Region

North America held the largest revenue share of nearly 44% in the historical period. This dominance is supported by advanced healthcare infrastructure, strong regulatory frameworks, and high investment in biomanufacturing capabilities. The presence of leading biologics manufacturers, increasing biologic approvals, and growing adoption of advanced therapies are further driving regional growth, reinforcing its leading position in the global market.

##### Leading Players in the Biologics Market

The key features of the market report comprise patent analysis, funding analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

AbbVie Inc.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

AbbVie Inc. is a U.S.-based biopharmaceutical company headquartered in North Chicago, Illinois, founded in 2013. It focuses on immunology, oncology, neuroscience, and aesthetics, with a strong biologics portfolio including monoclonal antibody therapies such as Humira and Skyrizi. The company emphasizes advanced biologic innovation and global commercialization. In December 2024, AbbVie acquired ImmunoGen to strengthen its oncology pipeline and expand antibody-drug conjugate capabilities.

Amgen Inc.

Amgen Inc. is a U.S.-based biotechnology company headquartered in Thousand Oaks, California, established in 1980. It specializes in oncology, cardiovascular disease, inflammation, and bone health, with a diverse biologics portfolio including biosimilar products and innovative therapies. The company is a leader in biologic drug development and commercialization. In October 2023, Amgen completed its USD 27.8 billion acquisition of Horizon Therapeutics, expanding its rare disease and biologics portfolio.

Lilly (Eli Lilly and Company)

Eli Lilly and Company is a U.S.-based pharmaceutical firm headquartered in Indianapolis, Indiana, founded in 1876. It focuses on diabetes, oncology, immunology, and neuroscience, with a growing biologics pipeline including gene therapy biologic and antibody-based treatments. The company is expanding its advanced therapeutics capabilities globally. In November 2023, Lilly acquired POINT Biopharma to enhance its oncology biologics and radiopharmaceutical portfolio.

F. Hoffmann-La Roche AG

F. Hoffmann-La Roche AG is a Switzerland-based pharmaceutical company headquartered in Basel, founded in 1896. It is a global leader in oncology, diagnostics, and immunology, with a robust portfolio including biologics such as antibody-drug conjugate therapies. Roche is known for pioneering precision medicine and targeted biologics. In October 2024, Roche announced positive Phase III results for its breast cancer biologic therapy enhancing oncology pipeline strength.

Other key players in the market are Samsung Biologics, Sanofi, Pfizer Inc., Merck & Co., Inc., Novo Nordisk A/S, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Celltrion Inc., BD, Bayer AG, and AstraZeneca.

Key Questions Answered in the Biologics Market

- What was the biologics market value in 2025?
- What is the biologics market forecast outlook for 2026-2035?
- What major factors aid the demand for biologics market?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major biologics market trends?
- Which source is expected to dominate the market segment?
- Which product is expected to dominate the market segment?
- Which indication is projected to lead the market segment?
- Which distribution channel is likely to lead the market segment?
- Who are the key players in the biologics market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

More Insights On

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Spine Biologics Market

Orthobiologics Market

## **Table of Contents:**

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Biologics Market Overview
- 3.1 Global Biologics Market Historical Value (2019-2025)
- 3.2 Global Biologics Market Forecast Value (2026-2035)
- 4 Global Biologics Market Landscape\*
- 4.1 Global Biologics Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Biologics Product Landscape
- 4.2.1 Analysis by Source
- 4.2.2 Analysis by Product
- 5 Global Biologics Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter's Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Biologics Market Segmentation (219-2035)
- 6.1 Global Biologics Market (2019-2035) by Source
- 6.1.1 Market Overview
- 6.1.2 Microbial
- 6.1.3 Mammalian

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2 Global Biologics Market (2019-2035) by Product
  - 6.2.1 Market Overview
  - 6.2.2 Monoclonal Antibodies
    - 6.2.2.1 Human mABs
    - 6.2.2.2 Humanized mABs
    - 6.2.2.3 Chimeric mABs
    - 6.2.2.4 Murine mABs
  - 6.2.3 Vaccines
  - 6.2.4 Recombinant Proteins
  - 6.2.5 Antisense, RNAi & molecular therapy
  - 6.2.6 Cell Based Therapies
    - 6.2.6.1 Stem Cell Therapy
    - 6.2.6.2 CAR-T Cell Therapy
  - 6.2.7 Tissue Engineering
  - 6.2.8 Others
- 6.3 Global Biologics Market (2019-2035) by Indication
  - 6.3.1 Market Overview
  - 6.3.2 Oncology
  - 6.3.3 Immunological Disorders
  - 6.3.4 Cardiovascular Disorders
  - 6.3.5 Hematological Disorders
  - 6.3.6 Others
- 6.4 Global Biologics Market (2019-2035) by Distribution Channel
  - 6.4.1 Hospital Pharmacies
  - 6.4.2 Retail Pharmacies
  - 6.4.3 Online Pharmacies
- 6.5 Global Biologics Market (2019-2035) by Region
  - 6.5.1 Market Overview
  - 6.5.2 North America
  - 6.5.3 Europe
  - 6.5.4 Asia Pacific
  - 6.5.5 Latin America
  - 6.5.6 Middle East and Africa
- 7 North America Biologics Market (2019-2035)
  - 7.1 North America Biologics Market (2019-2035) by Source
    - 7.1.1 Market Overview
    - 7.1.2 Microbial
    - 7.1.3 Mammalian
  - 7.2 North America Biologics Market (2019-2035) by Product
    - 7.2.1 Market Overview
    - 7.2.2 Monoclonal Antibodies
      - 7.2.2.1 Human Monoclonal Antibodies
      - 7.2.2.2 Humanized Monoclonal Antibodies
      - 7.2.2.3 Chimeric Monoclonal Antibodies
      - 7.2.2.4 Murine Monoclonal Antibodies
    - 7.2.3 Vaccines
    - 7.2.4 Recombinant Proteins

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.2.5 Antisense, RNAi & molecular therapy
- 7.2.6 Cell Based Therapies
  - 7.2.6.1 Stem Cell Therapy
  - 7.2.6.2 CAR-T Cell Therapy
- 7.2.7 Tissue Engineering
- 7.2.8 Others
- 7.3 North America Biologics Market (2019-2035) by Country
  - 7.3.1 United States of America
  - 7.3.2 Canada
- 8 Europe Biologics Market (219-2035)
  - 8.1 Europe Biologics Market (2019-2035) by Source
    - 8.1.1 Market Overview
    - 8.1.2 Microbial
    - 8.1.3 Mammalian
  - 8.2 Europe Biologics Market (2019-2035) by Product
    - 8.2.1 Market Overview
    - 8.2.2 Monoclonal Antibodies
      - 8.2.2.1 Human mABs
      - 8.2.2.2 Humanized mABs
      - 8.2.2.3 Chimeric mABs
      - 8.2.2.4 Murine mABs
    - 8.2.3 Vaccines
    - 8.2.4 Recombinant Proteins
    - 8.2.5 Antisense, RNAi & molecular therapy
    - 8.2.6 Cell Based Therapies
      - 8.2.6.1 Stem Cell Therapy
      - 8.2.6.2 CAR-T Cell Therapy
    - 8.2.7 Tissue Engineering
    - 8.2.8 Others
  - 8.3 Europe Biologics Market (2019-2035) by Country
    - 8.3.1 United Kingdom
    - 8.3.2 Germany
    - 8.3.3 France
    - 8.3.4 Italy
    - 8.3.5 Others
- 9 Asia Pacific Biologics Market (219-2035)
  - 9.1 Asia Pacific Biologics Market (2019-2035) by Source
    - 9.1.1 Market Overview
    - 9.1.2 Microbial
    - 9.1.3 Mammalian
  - 9.2 Asia Pacific Biologics Market (2019-2035) by Product
    - 9.2.1 Market Overview
    - 9.2.2 Monoclonal Antibodies
      - 9.2.2.1 Human mABs
      - 9.2.2.2 Humanized mABs
      - 9.2.2.3 Chimeric mABs
      - 9.2.2.4 Murine mABs

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2.3 Vaccines
- 9.2.4 Recombinant Proteins
- 9.2.5 Antisense, RNAi & molecular therapy
- 9.2.6 Cell Based Therapies
  - 9.2.6.1 Stem Cell Therapy
  - 9.2.6.2 CAR-T Cell Therapy
- 9.2.7 Tissue Engineering
- 9.2.8 Others
- 9.3 Asia Pacific Biologics Market (2019-2035) by Country
  - 9.3.1 China
  - 9.3.2 Japan
  - 9.3.3 India
  - 9.3.4 Australia
  - 9.3.5 ASEAN
  - 9.3.6 Others
- 10 Latin America Biologics Market (2019-2035)
  - 10.1 Latin America Biologics Market (2019-2035) by Source
    - 10.1.1 Market Overview
    - 10.1.2 Microbial
    - 10.1.3 Mammalian
  - 10.2 Latin America Biologics Market (2019-2035) by Product
    - 10.2.1 Market Overview
    - 10.2.2 Monoclonal Antibodies
      - 10.2.2.1 Human mABs
      - 10.2.2.2 Humanized mABs
      - 10.2.2.3 Chimeric mABs
      - 10.2.2.4 Murine mABs
    - 10.2.3 Vaccines
    - 10.2.4 Recombinant Proteins
    - 10.2.5 Antisense, RNAi & molecular therapy
    - 10.2.6 Cell Based Therapies
      - 10.2.6.1 Stem Cell Therapy
      - 10.2.6.2 CAR-T Cell Therapy
    - 10.2.7 Tissue Engineering
    - 10.2.8 Others
  - 10.3 Latin America Biologics Market (2019-2035) by Country
    - 10.3.1 Brazil
    - 10.3.2 Argentina
    - 10.3.3 Mexico
    - 10.3.4 Others
- 11 Middle East and Africa Biologics Market (2019-2035)
  - 11.1 Middle East and Africa Biologics Market (2019-2035) by Source
    - 11.1.1 Market Overview
    - 11.1.2 Microbial
    - 11.1.3 Mammalian
  - 11.2 Middle East and Africa Biologics Market (2019-2035) by Product
    - 11.2.1 Market Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.2 Monoclonal Antibodies
  - 11.2.2.1 Human mABs
  - 11.2.2.2 Humanized mABs
  - 11.2.2.3 Chimeric mABs
  - 11.2.2.4 Murine mABs
- 11.2.3 Vaccines
- 11.2.4 Recombinant Proteins
- 11.2.5 Antisense, RNAi & molecular therapy
- 11.2.6 Cell Based Therapies
  - 11.2.6.1 Stem Cell Therapy
  - 11.2.6.2 CAR-T Cell Therapy
- 11.2.7 Tissue Engineering
- 11.2.8 Others
- 11.3 Middle East and Africa Biologics Market (2019-2035) by Country
  - 11.3.1 Saudi Arabia
  - 11.3.2 United Arab Emirates
  - 11.3.3 Nigeria
  - 11.3.4 South Africa
  - 11.3.5 Others
- 12 Regulatory Framework
  - 12.1 Regulatory Overview
    - 12.1.1 US FDA
    - 12.1.2 EU EMA
    - 12.1.3 INDIA CDSCO
    - 12.1.4 JAPAN PMDA
    - 12.1.5 Others
- 13 Patent Analysis
  - 13.1 Analysis by Type of Patent
  - 13.2 Analysis by Publication Year
  - 13.3 Analysis by Issuing Authority
  - 13.4 Analysis by Patent Age
  - 13.5 Analysis by CPC Analysis
  - 13.6 Analysis by Patent Valuation
  - 13.7 Analysis by Key Players
- 14 Grants Analysis
  - 14.1 Analysis by Year
  - 14.2 Analysis by Amount Awarded
  - 14.3 Analysis by Issuing Authority
  - 14.4 Analysis by Grant Application
  - 14.5 Analysis by Funding Institute
  - 14.6 Analysis by NIH Departments
  - 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
  - 15.1 Analysis by Funding Instances
  - 15.2 Analysis by Type of Funding
  - 15.3 Analysis by Funding Amount
  - 15.4 Analysis by Leading Players

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
  - 16.1 Analysis by Partnership Instances
  - 16.2 Analysis by Type of Partnership
  - 16.3 Analysis by Leading Players
  - 16.4 Analysis by Geography
- 17 Supplier Landscape (Customisable)
  - 17.1 AbbVie Inc.
    - 17.1.1 Company Overview
    - 17.1.2 Product Portfolio
    - 17.1.3 Demographic Reach and Achievements
    - 17.1.4 Mergers and Acquisitions
    - 17.1.5 Certifications
  - 17.2 Amgen Inc.
    - 17.2.1 Company Overview
    - 17.2.2 Product Portfolio
    - 17.2.3 Demographic Reach and Achievements
    - 17.2.4 Mergers and Acquisitions
    - 17.2.5 Certifications
  - 17.3 Lilly
    - 17.3.1 Company Overview
    - 17.3.2 Product Portfolio
    - 17.3.3 Demographic Reach and Achievements
    - 17.3.4 Mergers and Acquisitions
    - 17.3.5 Certifications
  - 17.4 F. Hoffmann-La Roche AG
    - 17.4.1 Company Overview
    - 17.4.2 Product Portfolio
    - 17.4.3 Demographic Reach and Achievements
    - 17.4.4 Mergers and Acquisitions
    - 17.4.5 Certifications
  - 17.5 Samsung Biologics
    - 17.5.1 Company Overview
    - 17.5.2 Product Portfolio
    - 17.5.3 Demographic Reach and Achievements
    - 17.5.4 Mergers and Acquisitions
    - 17.5.5 Certifications
  - 17.6 Sanofi
    - 17.6.1 Company Overview
    - 17.6.2 Product Portfolio
    - 17.6.3 Demographic Reach and Achievements
    - 17.6.4 Mergers and Acquisitions
    - 17.6.5 Certifications
  - 17.7 Pfizer Inc.
    - 17.7.1 Company Overview
    - 17.7.2 Product Portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Merck & Co., Inc.
  - 17.8.1 Company Overview
  - 17.8.2 Product Portfolio
  - 17.8.3 Demographic Reach and Achievements
  - 17.8.4 Mergers and Acquisitions
  - 17.8.5 Certifications
- 17.9 Novo Nordisk A/S
  - 17.9.1 Company Overview
  - 17.9.2 Product Portfolio
  - 17.9.3 Demographic Reach and Achievements
  - 17.9.4 Mergers and Acquisitions
  - 17.9.5 Certifications
- 17.10 Johnson & Johnson Services, Inc.
  - 17.10.1 Company Overview
  - 17.10.2 Product Portfolio
  - 17.10.3 Demographic Reach and Achievements
  - 17.10.4 Mergers and Acquisitions
  - 17.10.5 Certifications
- 17.11 Bristol-Myers Squibb Company
  - 17.11.1 Company Overview
  - 17.11.2 Product Portfolio
  - 17.11.3 Demographic Reach and Achievements
  - 17.11.4 Mergers and Acquisitions
  - 17.11.5 Certifications
- 17.12 Celltrion Inc.
  - 17.12.1 Company Overview
  - 17.12.2 Product Portfolio
  - 17.12.3 Demographic Reach and Achievements
  - 17.12.4 Mergers and Acquisitions
  - 17.12.5 Certifications
- 17.13 BD
  - 17.13.1 Company Overview
  - 17.13.2 Product Portfolio
  - 17.13.3 Demographic Reach and Achievements
  - 17.13.4 Mergers and Acquisitions
  - 17.13.5 Certifications
- 17.14 Bayer AG
  - 17.14.1 Company Overview
  - 17.14.2 Product Portfolio
  - 17.14.3 Demographic Reach and Achievements
  - 17.14.4 Mergers and Acquisitions
  - 17.14.5 Certifications
- 17.15 AstraZeneca
  - 17.15.1 Company Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- 18 Global Biologics Market - Distribution Model (Additional Insight)
  - 18.1 Overview
  - 18.2 Potential Distributors
  - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
  - 20.1 Very Small Companies
  - 20.2 Small Companies
  - 20.3 Mid-Sized Companies
  - 20.4 Large Companies
  - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
  - 21.1 Government Funded
  - 21.2 Private Insurance
  - 21.3 Out-of-Pocket

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Biologics Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)**

Market Report | 2026-05-20 | 350 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4949.00
	Five User License	\$5949.00
	Corporate License	\$6969.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-08"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

